8 High Growth UK Stocks to Invest In

3. Autolus Therapeutics (NASDAQ:AUTL)  

5-Year Revenue CAGR: 29.30% 

No of Hedge Funds: 24

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company that specializes in developing T-cell therapies for the treatment of cancer. Autolus Therapeutics (NASDAQ:AUTL) proprietary technology platform engineers T-cells to specifically target and destroy cancer cells, offering a highly personalized approach to cancer treatment.

Autolus Therapeutics’ (NASDAQ:AUTL) obe-cel, an autologous cell therapy for a type of blood and bone marrow cancer, has shown impressive results in clinical trials, with an objective response rate (ORR) of 78% in patients with r/r B-ALL, compared to an ORR of 65% for Tecartus, a competing therapy developed by Gilead Sciences. Additionally, obe-cel has demonstrated a favorable safety profile, with only 3% of patients experiencing grade 3 or higher cytokine release syndrome and 7% experiencing grade 3 or higher ICANS.

The market opportunity for obe-cel is significant, with an estimated 8,000 new cases of adults diagnosed globally each year. Autolus Therapeutics (NASDAQ:AUTL) anticipates that the addressable market for obe-cel will be approximately 3,000 patients, which translates to a market opportunity of around $1.5 billion.

One of the key advantages of obe-cel is its differentiated mechanism of action, which allows for a shorter half-life and less toxicity compared to other cancer cell therapies. Additionally, obe-cel is administered as two infusions using a tumor burden-guided dosing schedule, which could make it more appealing to patients and physicians. With a potential price point of around $450,000, obe-cel could be competitive with other cancer cell therapies on the market.

Autolus Therapeutics (NASDAQ:AUTL) is also exploring the use of obe-cel in autoimmune diseases, including systemic lupus erythematosus (SLE), another chronic autoimmune disease. The company has promised data from a study on SLE patients before the end of this year, which could provide additional insight for growth.

Autolus Therapeutics (NASDAQ:AUTL) has also established partnerships with three major pharmaceutical companies, including BioNTech, Moderna, and Bristol Myers Squibb, which could provide additional opportunities for growth and revenue.

Autolus Therapeutics’ (NASDAQ:AUTL) obe-cel has the potential to become a best-in-class cell therapy for the treatment of cancers. Industry analysts have a consensus Buy rating on the stock, with a target price of $10.40, indicating a potential gain of 86.10% from its current price.